Mixed Opening
Stocks appear set to open mixed to
higher Tuesday.
J.P. Morgan added Network Appliance
(
NTAP |
Quote |
Chart |
News |
PowerRating)
to its Focus List, stating they believe the company will outperform the peers in
its group.
Credit Suisse First Boston said it
believes Intel
(
INTC |
Quote |
Chart |
News |
PowerRating) will fall below Q3 guidance.
Micron Technologies
(
MU |
Quote |
Chart |
News |
PowerRating) was
downgraded by ABN Amro from Add to Hold and lowered its target from $25 to $21.
Morgan Stanley lowered Calendar Year
2002 estimates on Enterasys
(
ETS |
Quote |
Chart |
News |
PowerRating) from 39 cents to 30 cents. In addition,
they lowered revenue estimates from $970 million to $866 million.
J.P. Morgan added Sprint FON
(
FON |
Quote |
Chart |
News |
PowerRating)
to its Focus List with a $36 price target.
Compaq Computer
(
CPQ |
Quote |
Chart |
News |
PowerRating) has selected
E.piphany
(
EPNY |
Quote |
Chart |
News |
PowerRating) to improve the company’s customer service effectiveness.
Morgan Stanley lowered its rating on
Network Associates
(
NETA |
Quote |
Chart |
News |
PowerRating) from Strong Buy to Neutral.
Genaissance Pharmaceuticals
(
GNSC |
Quote |
Chart |
News |
PowerRating)
entered into an agreement with Pfizer
(
PZE |
Quote |
Chart |
News |
PowerRating) where Pfizer will utilize data from
GNSC’s HAP database.
Advance Micro Devices
(
AMD |
Quote |
Chart |
News |
PowerRating) is in
collaboration with Microsoft
(
MSFT |
Quote |
Chart |
News |
PowerRating) with regard to marketing the new AMD
Athlon XP processor and MSFT’s Windows XP.
Pediatrix Medical
(
PDX |
Quote |
Chart |
News |
PowerRating) raised its
Q3 outlook to come in between 39 and 40 cents a share vs. previous
estimates of 35 to 37 cents a share.
Benchmark Electronics
(
BHE |
Quote |
Chart |
News |
PowerRating)
reaffirmed Q3 earnings, but views revenues coming in at approximately $260
million vs. analyst estimates of $306.8 million.
Myriad Genetics
(
MYGN |
Quote |
Chart |
News |
PowerRating) said it
has discovered a novel drug targeted at treating a wide range of cancers.
Pre-clinical studies have shown that it has strong anti-cancer activity without
damaging or destroying normal human cells.
Semiconductor equipment maker
Electroglas
(
EGLS |
Quote |
Chart |
News |
PowerRating) warned on the September quarter. The company said that
revenues will come in well below its outlook provided in July.